Table 2

Indications, dosing, originator company and patent expiry dates for selected TKIs

MedicineIndication(s)*Dose(s)*Originator companyExpiry of term for base compound patent†Target price per patient per year
USAEU
Imatinib (Glivec/Gleevec)Chronic myeloid leukaemia400 mg QDNovartis20152016$128–$216
Erlotinib (Tarceva)Non-small cell lung cancer (locally advanced or metastatic)150 mg QDRoche20182020$240
Sorafenib (Nexavar)Renal cell carcinoma, Hepatocellular carcinoma400 mg BIDBayer and Onyx Pharmaceuticals20202020$1450
Lapatinib (Tyverb/Tykerb)Advanced breast cancer1500 mg QDNovartis20202023$4020
  • *References in online supplementary appendix 1.

  • †References for patent expiry dates are given in online supplementary appendix 2 and assume no supplementary patent term extensions.

  • BID, two times a day; QD, daily; TKI, tyrosine kinase inhibitor.